X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Orchid Chemicals with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs MYLAN (US) - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ORCHID PHARMA LTD   MYLAN
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
MYLAN
Dec-14
ORCHID PHARMA LTD/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1944,292-   
Low Rs353,025-   
Sales per share (Unadj.) Rs276.51,469.4-  
Earnings per share (Unadj.) Rs-79.2177.0-  
Cash flow per share (Unadj.) Rs-43.5284.9-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.9730.5-  
Shares outstanding (eoy) m70.45378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x0.42.5 16.6%   
Avg P/E ratio x-1.420.7 -7.0%  
P/CF ratio (eoy) x-2.612.8 -20.5%  
Price / Book Value ratio x2.15.0 42.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,0671,384,310 0.6%   
No. of employees `0002.825.0 11.2%   
Total wages/salary Rs m2,5270-   
Avg. sales/employee Rs Th6,956.122,239.8 31.3%   
Avg. wages/employee Rs Th902.50-   
Avg. net profit/employee Rs Th-1,993.02,679.1 -74.4%   
INCOME DATA
Net Sales Rs m19,477555,994 3.5%  
Other income Rs m407-3,241 -12.6%   
Total revenues Rs m19,884552,754 3.6%   
Gross profit Rs m1,103138,278 0.8%  
Depreciation Rs m2,51940,835 6.2%   
Interest Rs m5,22723,983 21.8%   
Profit before tax Rs m-6,23670,220 -8.9%   
Minority Interest Rs m20-288 -6.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1252,953 -4.2%   
Profit after tax Rs m-5,58066,979 -8.3%  
Gross profit margin %5.724.9 22.8%  
Effective tax rate %2.04.2 47.7%   
Net profit margin %-28.712.0 -237.8%  
BALANCE SHEET DATA
Current assets Rs m11,014488,793 2.3%   
Current liabilities Rs m32,060382,138 8.4%   
Net working cap to sales %-108.119.2 -563.3%  
Current ratio x0.31.3 26.9%  
Inventory Days Days9578 121.5%  
Debtors Days Days34107 31.3%  
Net fixed assets Rs m29,440128,628 22.9%   
Share capital Rs m70519,661 3.6%   
"Free" reserves Rs m2,0430-   
Net worth Rs m3,800276,384 1.4%   
Long term debt Rs m9,018412,891 2.2%   
Total assets Rs m46,5101,113,249 4.2%  
Interest coverage x-0.23.9 -4.9%   
Debt to equity ratio x2.41.5 158.9%  
Sales to assets ratio x0.40.5 83.8%   
Return on assets %-0.88.2 -9.3%  
Return on equity %-146.924.2 -606.0%  
Return on capital %-3.713.6 -27.4%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Net fx Rs m1,8650-   
CASH FLOW
From Operations Rs m1,68273,086 2.3%  
From Investments Rs m-9,860-57,638 17.1%  
From Financial Activity Rs m6,644-19,258 -34.5%  
Net Cashflow Rs m-1,535-3,810 40.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.02 Rs / USD

Compare ORCHID PHARMA LTD With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ORCHID PHARMA LTD With: PFIZER  J.B.CHEMICALS  ELDER PHARMA  PIRAMAL ENTERPRISES  STERLING BIOTECH  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views On News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Dec 17, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS